News | December 03, 2008

EchoCRT Trial Enrolls First Europeans to Investigate Resynchronization in Heart Failure Patients

December 4, 2008 - BIOTRONIK said this week the first European patients have been enrolled into the EchoCRT (Echocardiography guided Cardiac Resynchronization Therapy) trial by the team of physicians at Hospital Clinic in Barcelona, Spain.

The trial will be led by Professor Josep Brugada, M.D., director of the Thorax Institute, chairman of the cardiology department, EchoCRT Executive Committee member and president of the European Heart Rhythm Association. The EchoCRT trial is the largest prospective, randomized, double-blind, international, multicenter clinical trial of its kind. It is designed to demonstrate that optimal medical therapy plus CRT reduces all-cause mortality or first hospitalization for worsening heart failure in the study population compared to optimal medical therapy alone. Eligible patients must have echocardiographic evidence of left ventricular dyssynchrony (discoordinated pumping action of the heart) with a “narrow QRS” width (

Worldwide 125 sites will participate in EchoCRT and 80 of these sites are located in Europe and Australia. Overall, it is planned that 700 of the target 1,258 patients to be randomized to the study will be recruited from European sites in Austria, Belgium, Czech Republic, Denmark, France, Germany, Netherlands, Spain, Switzerland and the U.K.

Cardiac resynchronization therapy (CRT) is a proven, life-saving, device-based treatment for certain heart failure patients with ventricular dyssynchrony. Patients enrolled in the EchoCRT study are implanted with the Lumax HF-T CRT-D device. The maker said these new cardiac devices are equipped with pioneering features, such as BIOTRONIK Home Monitoring, providing the physician with automatic, remote updates on their patient’s cardiovascular and device status.

“EchoCRT will answer important questions about device-based treatment for hundreds of thousands of heart failure patients,” said Professor Frank Ruschitzka, M.D., University of Zürich, Executive Committee co-chairman and international co-principal investigator for EchoCRT. “We are looking forward to the results of EchoCRT to know whether the majority of heart failure patients can also benefit from device-based therapy.”

EchoCRT is an investigator clinical trial led by the University of Zürich. GE echocardiography equipment will be utilized throughout EchoCRT and GE, as a clinical cooperation partner to BIOTRONIK in this study, will provide training and technical support in order to reduce data variability and ensure optimal reliability of outcomes. BIOTRONIK is the sole sponsor of the EchoCRT study being conducted under an investigational device exemption (IDE) granted by the FDA.

For more information: www.biotronik.com

Related Content

Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population
News | Atrial Fibrillation| July 03, 2017
Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in...
Sponsored Content | Videos | Cardiovascular Ultrasound| June 29, 2017
Leyla Elif Sade, M.D., MESC, professor of cardiology at Başkent University, Ankara, Turkey, discusses use of echo for
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Sponsored Content | Videos | Leads Implantable Devices| May 25, 2017
Bruce Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, discusses advancemen
Overlay Init